8% Growth in Asia Pacific Presents Pharma Investors with Good Opportunities
London, UK -- (SBWire) -- 10/06/2017 --The Asia Pacific market for drugs to treat all medical conditions will be worth $255 billion in 2020, having grown from $185 billion in 2016. By 2020 the Asia Pacific market, which was already in 2016 the second largest in the world after North America, will have increased its lead over Western Europe in third place and made gains on North America.
The size and growth of a regional market such as Asia Pacific's for drugs as a whole is related to many factors - size of population, and especially of the older population, of course, and GDP per capita, but also regulatory systems and physician attitudes as well as disease incidence. New drugs tend to be more expensive, while those out of patent can see their price lowered dramatically by the advent of generics, which have seen major growth in India and China. Markets for drugs that can be bought without prescription, such as many for respiratory illnesses such as colds, can grow rapidly as this region's population become increasingly urban and gains access to pharmacies.
The Asia Pacific drugs market's largest segment in 2020 will be in musculoskeletal drugs for treating conditions such as arthritis and osteoporosis, closely followed by cancer drugs. Third largest will be cardiovascular drugs to treat heart-related conditions. Musculoskeletal drugs will have achieved its leading position in 2020 in Asia Pacific through a growth rate that far exceeds that of the other two big segments at 11.6% year on year from 2016. Cancer drugs will grow at 8% a year from 2016 to 2020 and cardiovascular at only 5%.
Other fast-growing segments in the region will be for drugs for blood disorders and metabolic disorders and drugs to treat respiratory illnesses but these are somewhat smaller markets.
The global pharma market as a whole was worth $886 billion in 2016 and will reach $1105 billion in 2020, growing at 5.7%, an accelerated pace compared to its 4.9% a year growth for the years before 2016.
The pharmaceutical drugs industry comprises establishments that develop drugs to diagnose, cure, treat or prevent diseases. Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subject to a number of laws and regulations that deal with patenting, testing, safety, efficacy and marketing and affect the size and growth rates of the market. Pharmaceutical companies produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.
Some trends shaping the market include an early switching of the product from prescription to non-prescription status and an increasing demand for new medicines for drug-resistant infections.
1) Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. A key example from the dermatology OTC drugs market for an early switch includes butenafine hydrochloride (Lotrimin Ultra), an anti-fungal drug. The product was reclassified and switched to being an OTC drug in December 2001, long before its patent expiry (April 2017). It is used in the treatment of athlete's foot, jock itch and ringworm infections.
2) The demand for new drug candidates for antimicrobial resistant infections is increasing. Antimicrobial resistance is a serious concern to global public health as it resulted in long duration of illness, the requirement of additional tests and use of more expensive drugs. Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, parasites and fungi change and adapted to drugs when they are exposed to antimicrobial drugs such as antibiotics, antivirals, antifungals, anthelmintics and others. According to World Health Organization (WHO), globally 4,80,000 people are developing multi-drug resistant TB each year and drug resistance is starting to complicate the treatment of malaria and HIV as well. Companies are investing in developing the new drug candidates to treat drug-resistant infections. For instance, in 2014, Cubist Pharmaceuticals launched a new antibiotic Zerbaxa (ceftolozane/tazobactam) for complicated intra-abdominal infections, complicated urinary tract infections and also for infections of the kidney (pyelonephritis) . Also, Johnson & Johnson launched Sirturo (bedaquiline) for pulmonary multi-drug resistant tuberculosis. In November 2013, Roche and Polyphor Ltd have entered into a licensing agreement to develop and commercialize Polyphor's investigational macrocycle antibiotic, POL7080 for the treatment of Pseudomonas aeruginosa bacterial infections which become resistant to many antibiotic treatments.
Where to Learn More
Read Pharmaceutical Drugs Market Global Report 2017 from The Business Research Company for information on the following:
Markets Covered: Cardiovascular Disorders, Dermatology, Gastrointestinal Diseases, Genito-Urinary Disorders, Hematology, Infectious Diseases, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Oncology, Ophthalmology, Respiratory Diseases
Companies Mentioned: Johnson & Johnson, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc., and Sanofi
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Pharmaceutical Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Interested to know more? Here is a full scope of Biologics and Pharmaceutical Drugs Market reports to explore:
1. Biologics Market Global Report 2017
2. Anti-infective Drugs Market Global Report 2017
3. Cardiovascular Drugs Market Global Report 2017
4. Central Nervous System Drugs Market Global Report 2017
5. Dermatology Drugs Market Global Report 2017
6. Genito-urinary Drugs Market Global Report 2017
7. Hematology Drugs Market Global Report 2017
8. Metabolic Disorder Drugs Market Global Report 2017
9. Musculoskeletal Disorders Drugs Market Global Report 2017
10. Ophthalmology Drugs Market Global Report 2017
11. Gastrointestinal Drugs Market Global Report 2017
12. Respiratory Drugs Market Global Report 2017
13. Oncology Drugs Market Global Report 2017
About The Business Research Company
Visit TheBusinesResearchCompany.com. The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has research professionals at its office in the UK, India, and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. The Business Research Company's management have more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations. The Business Research Company's Consultant have master's qualifications from top institutes and include MBAs, MSCs, CFAs and CAs. The Business Research Company's Consultants gain training and qualifications from the market Research Society and are trained in advanced research practices, techniques, and ethics.
Media Relations Contact
+44 207 1930 708
View this press release online at: http://rwire.com/873314